Related Experiment Video
Updated: Jul 16, 2026

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence
Published on: December 30, 2025
PKCzetaII is a target for degradation through the tumour suppressor protein pVHL
Xavier Iturrioz1, Peter J Parker
1Protein Phosphorylation Laboratory, Cancer Research UK, London Research Institute, 44 Lincoln's Inn Fields Laboratories, London WC2A 3PX, UK.
Abstract:
PKCzetaII is a rapidly degraded variant of PKCzeta that suppresses epithelial cell polarisation. It is shown here that PKCzetaII is a target for the E3 ligase and tumour suppressor Von Hippel-Lindau protein (pVHL). Deletion studies demonstrate that the C-terminal region is required for the pVHL and proteasome dependent turnover of PKCzetaII, however it is the N-terminal PB1 domain of PKCzetaII that is required for pVHL complex formation. Reciprocal deletion studies define the pVHL effector domain as the dominant PKCzetaII binding site. The results indicate that pVHL recruits PKCzetaII via its PB1 domain and causes ubiquitination and degradation via the distal C-terminus of PKCzetaII.
Insights
The Von Hippel-Lindau protein (pVHL) targets PKCzetaII for degradation, a variant that hinders epithelial cell polarization. This interaction, mediated by specific protein domains, involves ubiquitination and proteasomal breakdown of PKCzetaII.
Area of Science:
- Cell Biology
- Molecular Biology
- Cancer Research
Background:
- Protein kinase C zeta (PKCzeta) has variants, including PKCzetaII, which is rapidly degraded and inhibits epithelial cell polarization.
- The Von Hippel-Lindau protein (pVHL) is an E3 ligase and tumor suppressor involved in protein degradation pathways.
Purpose of the Study:
- To investigate the interaction between PKCzetaII and pVHL.
- To elucidate the molecular mechanisms underlying PKCzetaII degradation by pVHL.
Main Methods:
- Deletion studies of PKCzetaII and pVHL to identify interacting domains.
- Analysis of ubiquitination and proteasomal degradation pathways.
Main Results:
- PKCzetaII is a direct target for pVHL-mediated degradation.
- The N-terminal PB1 domain of PKCzetaII is crucial for pVHL complex formation.
- The C-terminal region of PKCzetaII is essential for pVHL and proteasome-dependent turnover.
- The pVHL effector domain is the primary binding site for PKCzetaII.
Conclusions:
- pVHL recruits PKCzetaII through its PB1 domain.
- pVHL induces ubiquitination and degradation of PKCzetaII via its C-terminus.
- This mechanism highlights a novel role for pVHL in regulating PKCzetaII stability and epithelial cell polarization.
Related Concept Videos
Abnormal Proliferation
The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
The Intrinsic Apoptotic Pathway
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...